2023 WCLC Abstract Submission

Early Registration for WCLC 2023 Is Now Open!

The IASLC invites you to be a part of IASLC’s ongoing success story and join us in Singapore for an exciting program with wide-ranging and multidisciplinary content.
Register for WCLC 2023
IASLC Molecular Atlas

IASLC's Atlas of Molecular Testing for Targeted Therapy in Lung Cancer

The IASLC’s latest Atlas provides a comprehensive overview of all current and emerging molecular targets, specimen acquisition, available assays, and reporting and interpretation of molecular testing results from both a diagnostic and clinical perspective.
Access the latest Atlas
Patient Advocacy Slider

Apply Now For IASLC's 2023 CCTA, Patient Advocate & STARS Programs

The IASLC is now accepting applications for the 2023 Cancer Care Team and Patient Advocate Educational Awards and the 2023 STARS Program!
Submit your applications
Early Registration for WCLC 2023 Is Now Open!
IASLC's Atlas of Molecular Testing for Targeted Therapy in Lung Cancer
Apply Now For IASLC's 2023 CCTA, Patient Advocate & STARS Programs

Homepage

The International Association for the Study of Lung Cancer

The IASLC is a global multidisciplinary organization dedicated to eradication of all forms of lung cancer. From provision of educational events around the world and virtually to research projects and publications that advance the science of lung cancer, the IASLC's members—consisting of medical, surgical, and radiation oncologists, as well as other thoracic oncology specialists such as nurses, basic scientists, pathologists, radiologists, pulmonologists, statisticians, patient research advocates, patients, and their caregivers—are raising the bar for care of patients with lung cancer.

Explore More

2023 WCLC Abstract Submissions Are Now Open

Abstract submissions for the 2023 World Conference on Lung Cancer are now open! The WCLC Program Committee invites you to participate by submitting your scientific abstract(s). All submissions will close on April 14th, 2023.

Learn More & Submit Here

ILCN In Focus

ILCN article

Narrow Focus Allows Pragmatica-Lung Trial to Minimize Eligibility Criteria, Significantly Reduce Data Collection, Researcher Says

In a recent interview with ILCN, Dr. Karen Reckamp discussed the overall survival implications from the phase II Lung-MAP study and how the phase III follow-up Pragmatica-Lung trial aims to confirm that specific endpoint.

Mar 07, 2023
Read more

2022 Annual Report

2022 was a mix of old and new. Learn more about our work and see how IASLC members remain at the forefront of scientific achievement in multiple disciplines. 

Read The Latest Annual Report
IASLC's Atlas of Molecular Testing for Targeted Therapy in Lung Cancer

IASLC's Atlas of Molecular Testing for Targeted Therapy in Lung Cancer

The IASLC’s latest Atlas provides a comprehensive overview of all current and emerging molecular targets, specimen acquisition, available assays, and reporting and interpretation of molecular testing results from both a diagnostic and clinical perspective. 
 

Access the Latest Atlas

IASLC POSITION STATEMENT ON TOBACCO CESSATION AFTER A CANCER DIAGNOSIS

Tobacco use is a well-established cause of cancer and contributes to about 1 in 3 cancer deaths. Whereas the harmful effects of smoking on health are well recognized, the negative impacts of continued smoking after a diagnosis of cancer are underappreciated. The substantial body of research reviewed in the 2014 US Surgeon General’s Report concluded that smoking by cancer patients and survivors causes adverse outcomes, including increased overall mortality and cancer-related mortality, greater risk of a second primary cancer, and associations with substantially worse toxicity from cancer treatments. The clinical effects of smoking after a cancer diagnosis also dramatically increase the cost of cancer care. The 2020 US Surgeon General’s Report reported that smoking cessation after a cancer diagnosis is associated with improved survival, and quitting smoking significantly benefits non-cancer-related health outcomes. The recommendations are available in English, Spanish, Portuguese, Japanese, Chinese, and Polish.

Read the Position Statement
IASLC Corporate Roundtable

IASLC's Corporate Roundtable

Born from feedback received during meetings with our Corporate Partners in 2022, the IASLC Corporate Roundtable brings IASLC leadership and Roundtable Member Representatives together to collaborate on solutions to big-picture challenges facing those working to conquer lung cancer and other thoracic malignancies. 

Join the IASLC's Corporate Roundtable

Our Impact

8,000+ members from over 100 countries, all united by a single goal: to conquer thoracic cancers worldwide.

Our Impact

8,000+ members from over 100 countries, all united by a single goal: to conquer thoracic cancers worldwide.

See More

Our Work

In Numbers

8,000+ members from over 100 countries, all united by a single goal: to conquer thoracic cancers worldwide.

Lung Cancer Policy Network Map

Provide a global review of lung cancer screening clinical trials, implementation studies, and organized programs. This map facilitates policy-level discussions drawing from real-world implementation around the world and drives a community of learning around LDCT (Low Dose Computed Tomography) screening.
Explore

The IASLC Staging Project

The IASLC Staging Project is a global effort to study and improve the current staging system for lung cancer, mesothelioma, thymic and esophageal cancer.
Explore more

Pathologic Response (PR) Project

Neoadjuvant therapies have unique advantages and opportunities in lung cancer and need further investigation. Currently, there is no established guidance on how to process and evaluate resected lung cancer specimens following neoadjuvant therapy in the setting of clinical trials and clinical practice. There is also a lack of precise definitions of the degree of pathologic response, including Major Pathologic Response (MPR) or Complete Pathologic Response (CPR). The IASLC PR Project was created to establish Pathologic Response (PR), Major Pathologic Response (MPR), and/or Complete Pathologic Response (CPR) in surgical resection specimens following neoadjuvant therapies as predictors of long-term clinical benefit in patients with resected stages I to III lung cancers. These recommendations are intended as guidance for clinical trials, although it is hoped they can be viewed as suggestions for good clinical practice outside of clinical trials, to improve the consistency of pathologic assessment of treatment response.
Explore

In numbers

8,000+ members from over 100 countries, all united by a single goal: to conquer thoracic cancers worldwide.
45
Years Experience
15K
Number of Research Awards Funded
20.121
JTO Impact Factor
8K+
Members

Upcoming Meetings & Webinars

View all Upcoming Events
Endorsed Event
Mar 31 - Apr 02 2023
March 30 - April 1, 2023

Texas Lung Cancer Conference

CME Accredited
Joint Event
Mar 29 - Apr 01 2023

2023 European Lung Cancer Congress

IASLC Meeting
Apr 05 - Apr 07 2023
April 5-7, 2023

IASLC 2023 Hot Topic Meeting: Small Cell Lung Cancer

Open the Site
JTO-CRR_Hero-0820 - Cropped.jpg

Journal of Thoracic Oncology & JTO Clinical and Research Reports

Lung and thoracic specialists count on the IASLC’s journals to provide perspective on innovation in prevention, detention, diagnosis and cutting-edge treatments. As a leading medical journal, JTO focuses on lung and thoracic cancers and is dedicated to presenting original research reviews and opinions from a wide range of disciplines within the medical community. JTO CRR, the official open access journal of the IASLC, complements the JTO by offering authors a gold open access publication option. 

Explore Our Journals